A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT07336472 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: IBI3003

Sponsor

Fortvita Biologics (USA)Inc.